DaVita Inc/ US23918K1088 /
2024-04-24 10:10:00 PM | Chg. -1.17 | Volume | Bid2:00:00 AM | Ask2:00:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
132.74USD | -0.87% | 472,887 Turnover: 38.39 mill. |
120.00Bid Size: 100 | 133.25Ask Size: 100 | 11.64 bill.USD | - | 17.42 |
GlobeNewswire
2023-11-17
Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial pres...
GlobeNewswire
2023-08-15
Elevar Therapeutics Names Dr. Chris Galloway Vice President of Clinical Development
GlobeNewswire
2022-03-21
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
GlobeNewswire
2022-03-07
The Oncology Institute Announces Promotions for Dr. Daniel Virnich and Dr. Matt Miller
GlobeNewswire
2022-02-10
Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022
GlobeNewswire
2021-10-07
Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Anima...
GlobeNewswire
2021-10-01
AAON Increases Board Size and Appoints Bruce Ware and David Stewart as Independent Directors
GlobeNewswire
2021-09-09
ACTION BEHAVIOR CENTERS HIRES NEW GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
GlobeNewswire
2021-09-09
Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development
GlobeNewswire
2021-08-11
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and ...
GlobeNewswire
2021-08-05
Vystar Details Preliminary Plans for RxAir Spin Off as Shareholder Dividend